Search clinical trials for: Placebo matching BMS-708163

Total 1439 results

Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated

Healthy

Japan
SIMR (Australia) Biotech Pty Ltd.

Completed

The Safety, Tolerability, and Pharmacokinetics (PK) of SR750 in Healthy Volunteers

Healthy Volunteers

Australia
Novartis Pharmaceuticals

Terminated

Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients

Ulcerative Colitis

Belgium, Hungary, Switzerland, Germany, Sweden, United Kingdom
Allergan

Completed

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine (ACHIEVE II)

Migraine, With or Without Aura

United States
Eisai Inc.

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult Subjects

Healthy Participants

United States
Heptares Therapeutics Limited
P1vital Limited

Completed

Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects

Alzheimer's Disease

United Kingdom
Kubota Vision Inc.
Otsuka Pharmaceutical Co., Ltd.

Completed

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

Geographic Atrophy | Dry Age-related Macular Degeneration

United States
Addex Pharma S.A.

Terminated

ADX10059 Migraine Prevention Study

Migraine

Germany, Austria, Belgium, France, United Kingdom
AstraZeneca
Bristol-Myers Squibb

Completed

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

Type 2 Diabetes

Mexico, Russian Federation, Spain, United States, Canada, Puerto Rico, Hungary, Peru, Romania, Poland, Germany, Czech Republic, India, Colombia, Denmark, Finland
Cognition Therapeutics

Completed

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer Disease

United States
Cognition Therapeutics

Completed

Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Australia
Bristol-Myers Squibb

Completed

Diabetic Peripheral Neuropathic Pain (DPNP)

Diabetic Peripheral Neuropathic Pain

United States, France
Respivert Ltd

Completed

A Study to Investigate the Safety and Tolerability of a New Inhaled Formulation of RV568 in Healthy Volunteers

Healthy Volunteers | COPD

United Kingdom
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants

Healthy Volunteers

China
Bristol-Myers Squibb

Completed

Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure

Acute Decompensated Heart Failure

United Kingdom, Israel, Argentina, Czechia, Greece, Poland
Bristol-Myers Squibb

Completed

A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986235 in Healthy Subjects

Mediators of Inflammation

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

Liver Fibrosis | Hepatic Cirrhosis

United States
Bristol-Myers Squibb

Completed

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Non-Alcoholic Steatohepatitis

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986278 Given to Healthy Participants

Healthy Participants

United Kingdom, Netherlands
Bristol-Myers Squibb

Completed

A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis

Psoriasis

Australia, Canada, Mexico
Bristol-Myers Squibb

Completed

A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Withdrawn

Japanese Bridging Study Conducted in the United States

Hepatitis C Virus

United States
Bristol-Myers Squibb

Completed

Safety Study of BMS-816336 in Healthy Male Subjects

Dyslipidemia | Diabetes Mellitus, Non-Insulin-Dependent

Australia
Bristol-Myers Squibb

Completed

A Study of BMS-562086 in Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Bristol-Myers Squibb

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis

Dermatitis, Atopic

Poland
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Terminated

A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction

Heart Failure

Spain, United Kingdom, Netherlands, Czechia, Poland
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults

Obese But Otherwise Healthy Participants

United States
Bristol-Myers Squibb

Terminated

A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

Rheumatoid Arthritis | Inflammatory Bowel Diseases | Psoriasis | Nonalcoholic Steatohepatitis | Ankylosing Spondylitis

Netherlands
Bristol-Myers Squibb

Completed

Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects

Severe Sepsis

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body

Liver Fibrosis/NASH

United States
Bristol-Myers Squibb

Withdrawn

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Scleroderma

United Kingdom, United States, Poland, Canada
Bristol-Myers Squibb

Completed

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

Dyslipidemia

Canada, Australia, United States
Bristol-Myers Squibb

Completed

Safety Study to Evaluate BMS-830216 in Healthy Subjects

Obesity

United States
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers

Healthy

Korea, Republic of
Bristol-Myers Squibb

Completed

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery (ADVANCE-2)

Deep Vein Thrombosis | Pulmonary Embolism

Italy, Korea, Republic of, China, Spain, South Africa, Colombia, Austria, France, Germany, Israel, Russian Federation, Denmark, Belgium, Singapore, Brazil, Mexico, Norway, Philippines, Poland, Ukraine, India, Malaysia, Hungary, Chile, Czech... and more
Cognition Therapeutics
National Institute on Aging (NIA); Alzheimer's Clinical Trials Consortium

Recruiting

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Early Alzheimer's Disease

United States
Gmax Biopharm Australia Pty Ltd.

Completed

Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106

Overweight and Obesity

Australia
Biogen
Denali Therapeutics Inc.

Recruiting

A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA)

Parkinson Disease

United States, Netherlands, Italy, Spain, Israel, Canada, China, Germany, France, Austria, United Kingdom, Poland, Japan
AbbVie

Recruiting

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Migraine

United States, Puerto Rico
Celldex Therapeutics

Active, not recruiting

A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Chronic Inducible Urticaria

United States, Latvia, Spain, Poland, Georgia, South Africa, Germany, Lithuania, Estonia, Hungary, Bulgaria
Celldex Therapeutics

Active, not recruiting

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

Spain, United States, Poland, Georgia, South Africa, Bulgaria, Hungary, Estonia, Germany
Biogen
Denali Therapeutics Inc.

Terminated

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (LIGHTHOUSE)

Parkinson Disease

United States, Italy, Spain, Germany, France, United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

United States
Alzheon Inc.
Quotient Clinical

Completed

Multiple Ascending Dose Study of ALZ-801

Alzheimer Disease

United Kingdom

3

Subscribe